Jeffrey Gregg

Natera has recently integrated Foresight’s phased-variant technology into the Signatera™ platform, combining ultrasensitive detection below 0.1 ppm with Natera’s market-leading commercial and operational infrastructure for MRD testing. This enhanced version of Signatera™ is offered alongside CLARITY™ and Latitude™, supporting tumor-informed and tissue-free MRD applications.

This Engager session will explore how incorporating additional variant classes enables the next level of ultrasensitivity and creates new opportunities for MRD-guided clinical trials.